XOMA (NASDAQ:XOMA) PT Raised to $117.00

XOMA (NASDAQ:XOMA) had its price target increased by HC Wainwright from $74.00 to $117.00 in a research note released on Thursday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for XOMA’s Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($0.96) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at $0.60 EPS.

A number of other research firms have also recently weighed in on XOMA. Leerink Partnrs restated an outperform rating on shares of XOMA in a research note on Monday, April 29th. SVB Leerink began coverage on XOMA in a research report on Monday, April 29th. They set an outperform rating and a $40.00 target price on the stock. Finally, StockNews.com raised XOMA from a sell rating to a hold rating in a report on Wednesday, August 14th.

XOMA Price Performance

Shares of XOMA opened at $28.13 on Thursday. The firm has a market capitalization of $327.41 million, a price-to-earnings ratio of -7.18 and a beta of 0.93. The firm’s fifty day simple moving average is $25.60 and its 200-day simple moving average is $24.83. XOMA has a twelve month low of $13.48 and a twelve month high of $30.36. The company has a current ratio of 9.45, a quick ratio of 9.45 and a debt-to-equity ratio of 1.39.

Institutional Trading of XOMA

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD purchased a new position in XOMA during the first quarter worth about $212,000. Bank of New York Mellon Corp boosted its position in shares of XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Rhumbline Advisers grew its stake in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,266 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.